[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": [
            "177Lu-FAP-2286",
            "68Ga-FAP-2286",
            "theranostic",
            "FAP-2286",
            "FAP",
            "fibroblast activation protein",
            "dosimetry",
            "CAF",
            "cancer-associated fibroblasts",
            "Peptide-Targeted Radioligand Therapy",
            "PTRT",
            "Peptide Receptor RadionuclideTherapy",
            "PRRT",
            "TRT",
            "Targeted radioligand therapy",
            "Target radionuclide therapy",
            "Lutetium-177",
            "Gallium-68"
        ],
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Clovis Oncology",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Be \u2265 18 years of age at the time the ICF is signed."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Consent to submission of archival tumor tissue, if available."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Adequate bone marrow, hepatic, and renal function."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "ECOG performance status of 0 or 1."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Life expectancy of at least 6 months."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Measurable disease per RECIST v1.1."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 6,
                    "description": "Active second malignancy that may interfere with the safety or efficacy assessments of this study"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 7,
                    "description": "Symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease or with primary tumor of CNS origin. Patients must be clinically stable for at least 4 weeks without steroid treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 8,
                    "description": "Received anticancer treatment \u2264 14 days prior to receiving study treatment (\u2264 28 days prior in case of checkpoint inhibitor or other antibody therapies)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 9,
                    "description": "Received prior radiopharmaceutical therapy or radioembolization, or prior extensive external beam radiation therapy (EBRT) to bone marrow or any prior EBRT to kidney, or received any EBRT within 2 weeks prior to administration of study treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 10,
                    "description": "Ongoing adverse effects from anticancer treatment > Grade 1, with the exception of alopecia"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 11,
                    "description": "Known incompatibility with contrast media for CT or PET scans. Infection requiring systemic antibiotics within 2 weeks prior to administration of study treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "Impaired cardiac function or clinically significant cardiac disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "Severe urinary incontinence, voiding dysfunction, or urinary obstruction"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "Minor surgery \u2264 5 days, or major surgery \u2264 21 days, prior to administration of study treatment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Any other condition that may increase the risk associated with study participation or interfere with its interpretation."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Refusal to use highly effective method of contraception, as applicable"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Pregnant or breastfeeding"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Any other condition that may increase the risk associated with study participation or interfere with its interpretation."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": null,
        "official_title": "LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 2 years)",
                "name": "Determine the recommended Phase 2 dose of 177Lu-FAP-2286 (Phase 1)",
                "description": "Incidence of adverse events, serious adverse events, and clinical laboratory abnormalities defined as dose-limiting toxicities (DLTs)",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From time of initial response until disease progression (up to approximately 2 years)",
                "name": "Duration of response (DOR) (Phase 2)",
                "description": "DOR per RECIST v1.1, as assessed by investigator",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug through at least 6-8 weeks after end of treatment (up to approximately 1 year)",
                "name": "Evaluate AEs and SAEs following administration of Safety of 68Ga-FAP-2286",
                "description": "Incidence of Analysis of adverse events (AEs) and serious adverse events (SAEs)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug through at least 6-8 weeks after end of treatment (Total Time Frame estimated up to approximately 6 years)",
                "name": "Further evaluate AEs, SAEs, and clinical laboratory abnormalities of 177Lu-FAP-2286 (Phase 2)",
                "description": "Incidence of adverse events, serious adverse events, and clinical laboratory abnormalities",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug until disease progression (up to approximately 2 years)",
                "name": "Objective response rate (ORR) (Phase 2)",
                "description": "Investigator-assessed Confirmed Response (CR) or Partial Response (PR) per RECIST v1.1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From first dose of study drug until death (up to approximately 3 years)",
                "name": "Overall survival (OS) (Phase 2)",
                "description": "Survival assessments conducted via visit or telephone call",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug to end of Cycle 6 with (each cycle ~ 6 weeks) (Total Time Frame estimated up to approximately 9 months)",
                "name": "Pharmacokinetics (PK) of 177Lu-FAP-2286 (Phase 1)",
                "description": "Area under the curve (AUC)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug to end of Cycle 6 with (each cycle ~ 6 weeks) (Total Time Frame estimated up to approximately 9 months)",
                "name": "Pharmacokinetics (PK) of 177Lu-FAP-2286 (Phase 1)",
                "description": "Clearance (CL)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug to end of Cycle 6 with (each cycle ~ 6 weeks) (Total Time Frame estimated up to approximately 9 months)",
                "name": "Pharmacokinetics (PK) of 177Lu-FAP-2286 (Phase 1)",
                "description": "Concentration at the end of infusion (Ceoi)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug to end of Cycle 6 with (each cycle ~ 6 weeks) (Total Time Frame estimated up to approximately 9 months)",
                "name": "Pharmacokinetics (PK) of 177Lu-FAP-2286 (Phase 1)",
                "description": "Half-half-life (t1/2)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug to end of Cycle 6 with (each cycle ~ 6 weeks) (Total Time Frame estimated up to approximately 9 months)",
                "name": "Pharmacokinetics (PK) of 177Lu-FAP-2286 (Phase 1)",
                "description": "Volume of distribution (Vd)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug until disease progression (up to approximately 2 years)",
                "name": "Preliminary efficacy of 177Lu-FAP-2286 in advanced solid tumors (Phase 1)",
                "description": "Investigator-assessed objective response by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug until disease progression (up to approximately 2 years)",
                "name": "Progression-free survival (PFS) (Phase 2)",
                "description": "Disease progression according to RECIST v1.1, as assessed by investigator, or death due to any cause",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of study drug until disease progression or end of treatment (up to approximately 9 months)",
                "name": "Radiation dosimetry of 177Lu-FAP-2286 (Phase 1)",
                "description": "Absorbed dose (gray [Gy]) estimated in organs and tumor lesions",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From time of screening FDG PET/CT to 68Ga-FAP-2286 PET/CT (up to approximately 1 month)",
                "name": "Tumor uptake of 68Ga-FAP-2286 as compared to 2-deoxy-2-[18F]fluoro-D-glucose (FDG) (Phase 1)",
                "description": "Comparison of SUVmax in tumor lesions",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Taken within 2 hours after 68Ga-FAP-2286 IV administration",
                "name": "Tumor uptake using 68Ga-FAP-2286 (Phase 1)",
                "description": "Maximum standardized uptake value (SUVmax) in tumor lesions assessed by PET/CT scan",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 3,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04939610",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-06-14",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrent Malignant Solid Neoplasm",
                    "Recurrent Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Solid Tumor",
                    "Metastatic Tumor",
                    "Metastatic Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Malignant Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Solid Neoplasm",
                    "Advanced Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127155",
                    "C9270"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Tumour",
                    "Solid tumor, NOS",
                    "Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Tumor",
                    "Tumor, metastatic",
                    "Neoplasm, metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, secondary",
                    "Secondary Tumor",
                    "Tumor, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Malignancy",
                    "Secondary Cancer"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C36255"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent",
                    "Recurrent Tumor",
                    "Neoplasm Recurrence"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C9305",
                    "C4798"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "CO-2286-114",
        "active_sites_count": 3,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radiolabeled Antibodies"
                        ],
                        "nci_thesaurus_concept_id": "C1511",
                        "name": "Radioimmunoconjugate",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C2124",
                            "C1512"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radioactive Pharmaceutical",
                            "Radiochemical",
                            "Radiopharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1446",
                        "name": "Radiopharmaceutical Compound",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug",
                            "Drug Substance",
                            "Pharmacological Substance",
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biomodulators",
                            "BRM",
                            "Biological Response Modifier",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunopotentiators",
                            "Immune Modulators",
                            "Immunotherapeutic Agent",
                            "Immunotherapy Agent",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Icon"
                        ],
                        "nci_thesaurus_concept_id": "C1512",
                        "name": "Immunoconjugate",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C307",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radiolabeled Antibodies"
                        ],
                        "nci_thesaurus_concept_id": "C1511",
                        "name": "Radioimmunoconjugate",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C2124",
                            "C1512"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C180806",
                        "name": "Lutetium Lu 177-FAP-2286",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C1511"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Biologicals",
                            "Biologics",
                            "Biological Products",
                            "Immunologics",
                            "Immunologic, Immunochemical"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radio Conjugates"
                        ],
                        "nci_thesaurus_concept_id": "C2124",
                        "name": "Radioconjugate",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1446"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug",
                            "Drug Substance",
                            "Pharmacological Substance",
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radioactive Pharmaceutical",
                            "Radiochemical",
                            "Radiopharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C1446",
                        "name": "Radiopharmaceutical Compound",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radio Conjugates"
                        ],
                        "nci_thesaurus_concept_id": "C2124",
                        "name": "Radioconjugate",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1446"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1512",
                        "name": "Immunoconjugate",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Gallium-68 labelled FAP-2286",
                            "68Ga-FAP-2286",
                            "Gallium-68-FAP-2286"
                        ],
                        "nci_thesaurus_concept_id": "C176457",
                        "name": "Gallium Ga 68 FAP-2286",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1511"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biomodulators",
                            "BRM",
                            "Biological Response Modifier",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunopotentiators",
                            "Immune Modulators",
                            "Immunotherapeutic Agent",
                            "Immunotherapy Agent",
                            "Immunomodulatory Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Biologicals",
                            "Biologics",
                            "Biological Products",
                            "Immunologics",
                            "Immunologic, Immunochemical"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Radiation",
                        "category": "other",
                        "parents": [
                            "C1909"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase 1: Dose Escalation",
                "description": "Up to 30 patients with solid tumors.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 1: RP2D Expansion Cohort",
                "description": "Up to 20 patients with solid tumors.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 2: Specific Solid Tumors",
                "description": "Cohorts of up to 40 patients each with Advanced or Solid Tumors",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2021-07632",
        "why_study_stopped": null,
        "brief_summary": "Phase 1 of this study will evaluate the safety and tolerability of 177Lu-FAP-2286 and\r\n      determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Phase 2\r\n      of this study is designed to evaluate objective response rate (ORR) in patients with specific\r\n      solid tumors.",
        "brief_title": "A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)",
        "status_history": [
            {
                "status_date": "2021-06-14T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 170,
        "_current_trial_status_sort_order": 0,
        "start_date": "2021-07-30",
        "record_verification_date": "2022-02-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": "LuMIERE",
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2026-06-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]